JournalQ1· SCImago 2025
Ophthalmology
ISSN 0161-6420
- Q1Quartile
- 3.00SJR
- 309h-index
- 5papers summarised
About this journal
Ophthalmology is a Q1 journal by SCImago Journal Rank (2025 data), with an SJR of 3.00 and an h-index of 309. Most of its papers in the Pofolia pool fall under Ophthalmology. Pofolia holds AI summaries of 5 paper(s) from this journal; the most cited is “Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050” (5477 citations).
The quartile (Q1–Q4) is the journal's percentile position within its subject area by SCImago Journal Rank; Q1 is the top 25%. What is a Q1 journal?
Papers we summarise from this journal
- Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 20502016 · 5477 citations
- Three-Year, Randomized, Sham-Controlled Trial of Dexamethasone Intravitreal Implant in Patients with Diabetic Macular Edema2014 · 1117 citations
- HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration2019 · 922 citations
- Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema: The 36-Month Results from Two Phase III Trials2013 · 823 citations
- Consensus Nomenclature for Reporting Neovascular Age-Related Macular Degeneration Data2019 · 803 citations
Journals in the same field
| Journal | Quartile | SJR | Summaries |
|---|---|---|---|
| New England Journal of Medicine | Q1 | 18.00 | 4 |
| Science | Q1 | 10.00 | 1 |
| Diabetes Care | Q1 | 7.00 | 3 |
| Progress in Retinal and Eye Research | Q1 | 5.00 | 4 |
| JAMA | Q1 | 5.00 | 3 |
| The Lancet Global Health | Q1 | 5.00 | 2 |
| Science Advances | Q1 | 4.00 | 1 |
| Proceedings of the National Academy of Sciences of the United States of America | Q1 | 3.00 | 2 |
| JAMA Ophthalmology | Q1 | 2.00 | 4 |
| Journal of the European Academy of Dermatology and Venereology | Q1 | 2.00 | 1 |
See every journal in the field →
Follow these journals on Pofolia
Pick your fields and new papers from their journals land in your feed every day with AI summaries. Free.
Start free